2022.04.01
In April 2022, Suzhou, China, Cure Genetics, a biotechnology company focusing on development of cutting-edge gene and cell therapies, announced that Dr. Robert R. Ruffolo has joined its Scientific Advisory Board (SAB). Where he will provide scientific guidance to Cure Genetics technology platform and R&D pipeline, as well as assisting the Company’s global partnership effort.
Dr. Ruffolo was formerly president and senior vice president (SVP) of R&D at Wyeth (now Pfizer), where he led a R&D team of over 9,000 scientists and managed an annual R&D budget of $3 billion. Prior to Wyeth, he was SVP of R&D at SmithKline Beecham Pharmaceuticals (now GSK). Dr. Ruffolo took an important part in the discovery and development of many successful products, including Carvedilol, Ropinirole, Dobutamine and Eprosartan, which also earned him several prestigious awards, including the 2008 PhRMA Award for Discovery.
"I look forward to working with the Cure Genetic R&D team. The Company is led by internationally renowned scientists with its cutting-edge exploration in the direction of cell and gene therapy, which I believe will lead to innovative treatments for serious diseases with significant unmet medical needs,” said Dr. Ruffolo. “For patients who currently have few treatment options, these innovative treatments will be life changing. There is no higher calling than focusing on developing new treatments to meet the urgent needs of these patients,”
"On behalf of Cure Genetics and the Board of Directors, I would like to welcome Dr. Robert Ruffolo to the Company's Scientific Advisory Board,” said Dr. Yuanyuan Xu, Chairman of Cure Genetics. “Bob is an outstanding scientist and a global leader in the field of new drug development, with his excellent scientific foundation, strategic thinking and business acumen, I believe Dr. Ruffolo will further enhance our ability innovate, and will play a positive role in strategic positioning of our pipeline and our global partnership efforts."
